sRAGE as severe acute bronchiolitis biomarker, prospective observational study

• Published in: Pediatric pulmonology Vol. 55; no. 12; pp. 3429 - 3436
• Main Authors: Sierra‐Colomina, Montserrat, García‐Salido, Alberto, Leoz‐Gordillo, Inés, Martínez de Azagra‐Garde, Amelia, Melen, Gustavo, García‐Teresa, María Ángeles, Iglesias‐Bouzas, Mabel, Nieto‐Moro, Montserrat, Ramírez‐Orellana, Manuel, Serrano‐González, Ana
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.12.2020
• Subjects: Babies; Biomarkers; Biomarkers - metabolism; bronchiolitis; Bronchiolitis - diagnosis; Bronchiolitis - metabolism; Bronchitis; C-Reactive Protein; Child; disease severity; Female; Hospitalization; Humans; Infant; infants; Inflammation; Intensive care; intensive care units; Intensive Care Units, Pediatric; Length of Stay; Lung - metabolism; Male; Medical diagnosis; Observational studies; pediatric; Prognosis; Prospective Studies; Receptor for Advanced Glycation End Products - metabolism; infants; disease severity; biomarkers; bronchiolitis; intensive care units; pediatric
• ISSN: 8755-6863; 1099-0496
• DOI: 10.1002/ppul.25048

Introduction and Objectives Acute bronchiolitis (AB) is the leading cause of hospitalization in infants and around 5% require intensive care treatment. Early identification of children diagnosed with AB at a high risk of severe progression is of great interest. The receptor for advanced glycation end products (RAGE), highly expressed in lung tissue, regulates immune responses and inflammation, and its soluble form, sRAGE, is believed to have an anti‐inflammatory role. We hypothesized serum sRAGE might be a major determinant of AB severity and prognosis. This study was conducted to measure serum sRAGE in infants with severe AB and to assess its correlation with clinical severity, immediate complications, and outcome. Methods Single‐center, prospective, observational study of hospitalized children with severe bronchiolitis admitted to the Pediatric Intensive Care Unit (PICU), from September 2015 to September 2016. Results A total of 52 children and 27 controls were included. The cases age ranged from 11 days to 21 months, resulting in a significant age difference with controls (11.85 vs 4.84 months, P < .01). Serum levels of sRAGE were lower but not significant in severe AB patients than in controls (1350.93 vs 1450.42 pg/mL; P = .399). No correlation was found between serum sRAGE and causative viruses, clinical symptoms, Wood‐Downes score (a clinical severity score) on admission, respiratory support, or length of hospital stay. Serum sRAGE was also lower in the cases having had a previous respiratory disease (1463.84 vs 1072.43 pg/mL; P = .049). However, it was higher in patients with any lung consolidation on the chest X‐ray (1584.79 vs 1131.62 pg/mL; P = .044) and weakly positively correlated with classical biomarkers (maximum C‐reactive protein, +0.295, P = .034; maximum procalcitonin, +0.309; P = .029). Conclusion This single‐center study reveals that sRAGE couldn't predict AB severity or outcome in children hospitalized at PICU. Nevertheless, it significantly increased in the presence of any lung consolidation and had a positive correlation with classical biomarkers. The utility of sRAGE in this population could be probably elucidated with a better understanding of AGE‐RAGE axis.